Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.66 |
| ▸ | CNR2 | P34972 | 4/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997267 | 0.94 | CNR1 (0.59) | CNR1CNR2KCNH2GABRA2GABRB2 | |
| SCHEMBL2865960 | 0.94 | CNR1 (0.61) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL12053889 | 0.93 | CNR1 (0.62) | CNR1CNR2KCNH2GABRA2GABRB2 | |
| SCHEMBL4000643 | 0.93 | GABRA2 (0.58) | CNR1CNR2KCNH2GABRA2GABRB2 | |
| SCHEMBL13672836 | 0.91 | CNR1 (0.57) | CNR1CNR2KCNH2GABRA2GABRB2 | |
| SCHEMBL30961554 | 0.90 | CNR1 (0.68) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL2627954 | 0.90 | CNR1 (0.68) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL2873286 | 0.90 | CNR1 (0.70) | CNR1CNR2KCNH2 | |
| Hydrochloric Acid SCHEMBL6543063 | 0.89 | CNR1 (0.69) | CNR1CNR2KCNH2 | |
| SCHEMBL4632916 | 0.88 | CNR1 (0.59) | CNR1CNR2GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354442-B2 | Imidazol-4-one and imidazole-4-thione compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-01-15 | — | — | US | disclosed |
| WO-2010062686-A2 | IMIDAZOL-4-ONE AND IMIDAZOLE-4-THIONE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-06 | — | — | US | disclosed |
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-02-26 | — | — | US | disclosed |
| US-6645985-B2 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them, and method of treating | SANOFI (FR) | 2003-11-11 | — | — | US | disclosed |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2002-12-12 | — | — | US | disclosed |
| US-6432984-B1 | CANNABINOID RECEPTOR ANTAGONISTS; TREATMENT OF OBESITY, DRUG ADDICTION, ALCHOLISM, PSYCHOLOGICAL, AND EATING DISORDERS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | CNR1 1/4885CNR2 2/4885KCNH2 3711/4885 |
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | CNR1, CNR2, HRH4 | CNR1 1/4885CNR2 2/4885KCNH2 1361/4885 |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | CNR1 1/4885CNR2 2/4885KCNH2 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.